Virax Biolabs Inks Multi-Country Supply Deal with Fosun Diagnostics for ImmuneSelect
VRAX sits 43% above its 52-week low of $2.5.
Summary
Virax Biolabs signed an exclusive commercial supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling product line across six Southeast Asian markets. The deal enables immediate purchase-order-driven revenue and provides access to Fosun's established regional infrastructure. This is a significant commercial milestone for Virax, which has been burning cash with minimal revenue and a going concern warning. The agreement offers a near-term revenue opportunity separate from its ViraxImmune diagnostic platform. Watch for initial purchase orders and revenue recognition in upcoming filings.
At the time of this announcement, VRAX was trading at $3.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $2.50 to $28.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.